Sam Fereidouni, MD
Family Medicine · Scottsdale, AZNPI 1003007048
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $370,461 of the $486,269 with a category attached, or 76.2%. 60 manufacturers reported payments, led by Lilly USA, LLC at 43.0% of the total. Among family medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,998 payments — averaging $243.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$209K
- Novo Nordisk$136K
- Bayer$35K
- Amgen$35K
- Abbott$23K
- Johnson & Johnson$14K
- plus $34K from 54 others
What the payments were for
- Consulting fees$14,9063%
- Speaking & faculty fees$370,46176%
- Travel & lodging$70,06214%
- Food & beverage$30,6216%
- Education$1580%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$155,634
- RYBELSUS$47,330
- Ozempic$44,208
- Repatha$33,096
- Kerendia$32,962
- Tresiba$20,785
- FREESTYLE LIBRE 3$14,089
- INVOKANA$13,548
- ZENPEP$11,441
- FreeStyle Libre 2$5,168
- STEGLATRO$3,790
- FreeStyle Libre Pro$3,375
- Saxenda$2,835
- SOLIQUA 100/33$1,155
- FARXIGA$725
- TOUJEO$624
- FreeStyle Libre$450
- BREZTRI$263
- XARELTO$231
- AIRSUPRA$133
How this compares
$486,269 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 271 | $438,814 |
| MounjaroTirzepatide | 214 | $252,584 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 85 | $132,479 |
| Xigduo XrDapaglifloz Propaned/Metformin | 101 | $101,342 |
| JardianceEmpagliflozin | 64 | $87,498 |
| RybelsusSemaglutide | 29 | $55,302 |
| Repatha SureclickEvolocumab | 39 | $48,776 |
| FarxigaDapagliflozin Propanediol | 42 | $48,060 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $48,022 |
| KerendiaFinerenone | 28 | $46,809 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $32,232 |
| EliquisApixaban | 24 | $30,708 |
| XareltoRivaroxaban | 19 | $27,370 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 22 | $24,693 |
| ProliaDenosumab | 14 | $24,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $135,751 | $512,203311 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev | $209,203 | $277,317241 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Trijardy Xr | $657 | $244,670171 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,362 | $59,24057 claims |
| GileadBiktarvy | $58 | $48,02212 claims |
| BayerKerendia | $34,814 | $46,80928 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix | $485 | $35,82596 claims |
| MerckJanumet Xr, Januvia | $4,131 | $31,99924 claims |
| PfizerEliquis | $710 | $30,70824 claims |
| Johnson & JohnsonXarelto | $13,990 | $27,37019 claims |
| AmgenProlia | $34,739 | $24,06214 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $2,248 | $20,07314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Scottsdale
- Renee DavisScottsdale$42K
- Joseph LilloScottsdale$30K
- Martin BlumeScottsdale$29K
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Jessica BlancoChandler$447K
- Heather ElwoodPhoenix$236K
- Ryan CaseyYuma$231K
- Suzanne BentzMesa$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.